Baidu
map

JAMA:氯沙坦不会增加心衰患者死亡风险

2012-04-25 陈智 中国医学论坛报

  丹麦的一项以国家登记注册为基础的队列研究显示,对于心力衰竭患者,同坎地沙坦相比,氯沙坦和死亡风险增加之间无相关性。尽管低剂量的氯沙坦与死亡增加存在相关,同最大剂量的坎地沙坦相比,高剂量氯沙坦并不会增加死亡发生。文献4月11日在线发表于《美国医学会杂志》(JAMA)。    

  丹麦的一项以国家登记注册为基础的队列研究显示,对于心力衰竭患者,同坎地沙坦相比,氯沙坦和死亡风险增加之间无相关性。尽管低剂量的氯沙坦与死亡增加存在相关,同最大剂量的坎地沙坦相比,高剂量氯沙坦并不会增加死亡发生。文献4月11日在线发表于《美国医学会杂志》(JAMA)。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]

相关资讯

JAMA:大剂量氯沙坦与心衰死亡增加无关

  据4月11日刊《美国医学会杂志》上的一项研究披露,尽管观察性研究提示,氯沙坦与其他同类药物[血管紧张素Ⅱ受体阻滞剂(ARB)]相比可能与心衰患者死亡风险升高有关,但一则包括了近6500名患者的分析发现,总的来说,与ARB坎地沙坦的使用相比,氯沙坦的使用与全因死亡或心血管性死亡的增加无关。   丹麦哥本哈根Statens Serum研究所的Henrik Svanstrom,

Baidu
map
Baidu
map
Baidu
map